Adoption of the income statement and balance sheet
The annual general meeting resolved to adopt the board of directors’ proposal for the income statement and the balance sheet for the fiscal year of 2023.

Disposition of the Company’s profit or loss
The annual general meeting resolved, in accordance with the board of directors’ proposal, that no dividend is paid and that the Company’s funds available for distribution is carried forward.

Discharge from liability
The annual general meeting resolved to grant discharge from liability to all persons who have had the position of board member or CEO in the Company during 2023.

Election on the board of directors and auditor, and determination of fees
The annual general meeting resolved to re-elect Lars-Erik Wernersson, Git Sturesjö Adolfsson and Thomas Rex as members of the board, and to elect Henric Stråth as a new board member. Thomas Rex was re-elected as chairman of the board of directors.

The annual general meeting resolved that the fees to the board of directors, for the period until the next annual meeting, shall be paid out with a total of fourteen (14) price base amounts (Sw. prisbasbelopp), of which five (5) price base amounts to the chairman and three (3) price base amounts to each of the other members elected by the annual general meeting who are not employed by the Company.

The annual general meeting resolved to re-elect the registered audit company KPMG AB as the Company’s auditor until the end of the next annual general meeting. Fees to the auditor shall be paid according to approved invoice.

Directed issue of warrants and approval of transfer of warrants
The annual general meeting resolved, in accordance with the board of directors’ proposal, on the warrant-based incentive program Warrant Program 2024/2028 by (A) issuance of warrants of series 2024/2028 to the Company’s wholly-owned subsidiary and (B) approval of the transfer of warrants 2024/2028 from the subsidiary to individuals who are or will be employed by the Company (individuals employed for a fixed time period are excluded) including the CEO (“Employees”).

No more than 500,000 warrants shall be issued to the subsidiary with the right and obligation for the subsidiary to later transfer the warrants to the Employees. The warrants shall be transferred by the subsidiary on 22 November 2024, or on the later date decided by the board of directors, the transfer shall be made at market value at the respective transfer dates and warrants shall be allotted in accordance with the principles set forth in the board of directors’ proposal. Subscription of shares under the warrants may take place during the period from 15 February 2028 until 30 April 2028. The premium per share shall be transferred to the free share premium reserve (Sw. fria överkursfonden). The subscription price per share shall correspond to 150 per cent of the volume-weighted average price according to Nasdaq First North Growth Market’s official curriculum list for shares in the Company during the period of ten (10) trading days ending on 15 November 2024, however, the subscription price per share shall never be less than the quota value of the share. The maximum dilution effect of the program is approximately 1.84 per cent.

________________

For more detailed information regarding the content of the resolutions, please refer to the press release published on 12 March 2024 and the complete notice of the annual general meeting. The notice of the annual general meeting and complete proposals regarding the resolutions of the annual general meeting are available on the Company’s website, www.acconeer.com.